Concepts (177)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Carcinoma, Pancreatic Ductal | 9 | 2025 | 1755 | 1.870 |
Why?
|
Pancreatic Neoplasms | 11 | 2025 | 5442 | 1.290 |
Why?
|
Leukemia, Large Granular Lymphocytic | 3 | 2013 | 24 | 1.270 |
Why?
|
Leucovorin | 2 | 2021 | 643 | 0.800 |
Why?
|
Fluorouracil | 2 | 2021 | 1656 | 0.640 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2018 | 109 | 0.580 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2018 | 259 | 0.550 |
Why?
|
Retroperitoneal Neoplasms | 1 | 2020 | 335 | 0.540 |
Why?
|
Liver Neoplasms | 3 | 2021 | 4362 | 0.530 |
Why?
|
Lymphoma, B-Cell, Marginal Zone | 2 | 2015 | 180 | 0.470 |
Why?
|
Peritoneal Neoplasms | 1 | 2020 | 715 | 0.440 |
Why?
|
Fever | 1 | 2020 | 1622 | 0.410 |
Why?
|
Thrombocytopenia | 1 | 2020 | 1183 | 0.400 |
Why?
|
Cellulitis | 1 | 2014 | 209 | 0.400 |
Why?
|
Peptides | 2 | 2021 | 4368 | 0.400 |
Why?
|
Inappropriate ADH Syndrome | 1 | 2012 | 61 | 0.400 |
Why?
|
Immunotherapy | 3 | 2022 | 4728 | 0.380 |
Why?
|
Superior Vena Cava Syndrome | 1 | 2012 | 56 | 0.380 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 4 | 2024 | 11843 | 0.380 |
Why?
|
Adrenal Gland Diseases | 1 | 2012 | 141 | 0.370 |
Why?
|
Antineoplastic Agents | 6 | 2020 | 13708 | 0.370 |
Why?
|
Proteomics | 1 | 2024 | 3901 | 0.360 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2014 | 647 | 0.350 |
Why?
|
Vascular Neoplasms | 1 | 2012 | 167 | 0.350 |
Why?
|
Deoxycytidine | 1 | 2014 | 888 | 0.330 |
Why?
|
Hematologic Diseases | 1 | 2013 | 499 | 0.330 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 1 | 2012 | 695 | 0.320 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2021 | 2331 | 0.310 |
Why?
|
Adenocarcinoma | 3 | 2016 | 6400 | 0.300 |
Why?
|
Waldenstrom Macroglobulinemia | 2 | 2014 | 1077 | 0.300 |
Why?
|
Catheter Ablation | 1 | 2021 | 2775 | 0.290 |
Why?
|
Autoimmune Diseases | 3 | 2015 | 2260 | 0.290 |
Why?
|
Lung Neoplasms | 3 | 2020 | 13589 | 0.260 |
Why?
|
Autoimmunity | 1 | 2014 | 1361 | 0.260 |
Why?
|
Esophageal Neoplasms | 1 | 2016 | 1676 | 0.250 |
Why?
|
Stomach Neoplasms | 1 | 2016 | 1484 | 0.250 |
Why?
|
Immunoconjugates | 2 | 2024 | 968 | 0.230 |
Why?
|
Hodgkin Disease | 1 | 2011 | 1386 | 0.220 |
Why?
|
Hemorrhage | 2 | 2013 | 3458 | 0.220 |
Why?
|
Hematologic Neoplasms | 1 | 2014 | 1905 | 0.210 |
Why?
|
Protein Kinase Inhibitors | 1 | 2018 | 5709 | 0.190 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2011 | 1644 | 0.170 |
Why?
|
Amphetamine-Related Disorders | 1 | 2020 | 81 | 0.170 |
Why?
|
Colonic Neoplasms | 1 | 2012 | 2544 | 0.170 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2014 | 3253 | 0.170 |
Why?
|
Niacinamide | 1 | 2021 | 419 | 0.160 |
Why?
|
Xenograft Model Antitumor Assays | 4 | 2020 | 3619 | 0.160 |
Why?
|
Pregnancy Complications | 1 | 2012 | 2969 | 0.150 |
Why?
|
MAP Kinase Kinase Kinase 1 | 1 | 2018 | 56 | 0.150 |
Why?
|
Humans | 38 | 2025 | 768451 | 0.150 |
Why?
|
Phenylurea Compounds | 1 | 2021 | 532 | 0.150 |
Why?
|
Organoids | 2 | 2022 | 749 | 0.150 |
Why?
|
Valproic Acid | 1 | 2020 | 443 | 0.150 |
Why?
|
Liposomes | 1 | 2021 | 792 | 0.140 |
Why?
|
Kidney Neoplasms | 1 | 2013 | 4298 | 0.130 |
Why?
|
Gastrointestinal Neoplasms | 1 | 2024 | 959 | 0.130 |
Why?
|
Neoplasm Metastasis | 3 | 2024 | 4931 | 0.130 |
Why?
|
Receptors, CXCR4 | 1 | 2020 | 729 | 0.120 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 1 | 2018 | 639 | 0.120 |
Why?
|
Tumor Microenvironment | 3 | 2024 | 3939 | 0.120 |
Why?
|
Aged, 80 and over | 9 | 2025 | 59680 | 0.120 |
Why?
|
Red-Cell Aplasia, Pure | 1 | 2014 | 27 | 0.120 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2020 | 1104 | 0.110 |
Why?
|
Hemangioendothelioma, Epithelioid | 1 | 2014 | 54 | 0.110 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2020 | 5342 | 0.110 |
Why?
|
Angiogenesis Inhibitors | 2 | 2014 | 2062 | 0.110 |
Why?
|
Bile Ducts | 1 | 2014 | 288 | 0.110 |
Why?
|
Pancytopenia | 1 | 2014 | 102 | 0.110 |
Why?
|
Hepatitis B Surface Antigens | 1 | 2014 | 294 | 0.110 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2020 | 958 | 0.110 |
Why?
|
Pyoderma Gangrenosum | 1 | 2014 | 86 | 0.110 |
Why?
|
Pneumonia, Bacterial | 1 | 2016 | 319 | 0.110 |
Why?
|
Aged | 10 | 2025 | 171520 | 0.100 |
Why?
|
Lymphatic Metastasis | 1 | 2020 | 2930 | 0.100 |
Why?
|
Male | 16 | 2025 | 364781 | 0.100 |
Why?
|
Mycophenolic Acid | 1 | 2013 | 350 | 0.090 |
Why?
|
Vena Cava, Superior | 1 | 2012 | 197 | 0.090 |
Why?
|
Immunosuppressive Agents | 2 | 2013 | 4213 | 0.090 |
Why?
|
Treatment Outcome | 4 | 2021 | 65409 | 0.090 |
Why?
|
Blood Platelets | 1 | 2020 | 2485 | 0.080 |
Why?
|
Nanoparticles | 1 | 2021 | 1986 | 0.080 |
Why?
|
Vasculitis | 1 | 2013 | 524 | 0.080 |
Why?
|
Thalidomide | 1 | 2014 | 885 | 0.080 |
Why?
|
Hepatitis B | 1 | 2014 | 707 | 0.080 |
Why?
|
Interferon-alpha | 1 | 2013 | 909 | 0.080 |
Why?
|
Genomics | 1 | 2025 | 5909 | 0.080 |
Why?
|
Single-Cell Analysis | 1 | 2020 | 2531 | 0.080 |
Why?
|
Lymph Nodes | 1 | 2020 | 3472 | 0.080 |
Why?
|
Gene Expression Regulation, Neoplastic | 3 | 2020 | 8635 | 0.080 |
Why?
|
Prevalence | 3 | 2015 | 15880 | 0.080 |
Why?
|
Boronic Acids | 1 | 2012 | 915 | 0.080 |
Why?
|
Middle Aged | 9 | 2025 | 223418 | 0.080 |
Why?
|
Rheumatic Diseases | 1 | 2014 | 664 | 0.070 |
Why?
|
Venous Thromboembolism | 1 | 2020 | 1884 | 0.070 |
Why?
|
Sodium | 1 | 2012 | 1595 | 0.070 |
Why?
|
Pyrazines | 1 | 2012 | 1206 | 0.070 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2020 | 3108 | 0.070 |
Why?
|
Methotrexate | 1 | 2013 | 1722 | 0.070 |
Why?
|
Female | 10 | 2025 | 396943 | 0.070 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2020 | 4642 | 0.070 |
Why?
|
Animals | 8 | 2025 | 169418 | 0.070 |
Why?
|
Interleukin-2 | 1 | 2013 | 1894 | 0.070 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2013 | 1797 | 0.060 |
Why?
|
Survival Rate | 1 | 2020 | 12875 | 0.060 |
Why?
|
Cancer Vaccines | 1 | 2013 | 1044 | 0.060 |
Why?
|
Multiple Myeloma | 2 | 2014 | 5192 | 0.060 |
Why?
|
Attention Deficit Disorder with Hyperactivity | 1 | 2020 | 3742 | 0.060 |
Why?
|
Prospective Studies | 5 | 2022 | 54914 | 0.060 |
Why?
|
Colorectal Neoplasms | 1 | 2024 | 6978 | 0.060 |
Why?
|
Disease Models, Animal | 2 | 2020 | 18388 | 0.060 |
Why?
|
Nervous System Diseases | 1 | 2014 | 1668 | 0.050 |
Why?
|
Lung Diseases | 1 | 2013 | 1926 | 0.050 |
Why?
|
Kidney Diseases | 1 | 2014 | 2102 | 0.050 |
Why?
|
Membrane Proteins | 1 | 2020 | 7895 | 0.050 |
Why?
|
Adult | 5 | 2025 | 223542 | 0.050 |
Why?
|
Mice | 5 | 2025 | 82045 | 0.050 |
Why?
|
Tumor Cells, Cultured | 2 | 2020 | 6135 | 0.050 |
Why?
|
Microsatellite Repeats | 1 | 2024 | 784 | 0.050 |
Why?
|
Amino Acids, Branched-Chain | 1 | 2024 | 269 | 0.050 |
Why?
|
Recurrence | 1 | 2014 | 8510 | 0.050 |
Why?
|
Maximum Tolerated Dose | 1 | 2024 | 890 | 0.050 |
Why?
|
Glutamine | 1 | 2024 | 578 | 0.050 |
Why?
|
Microsatellite Instability | 1 | 2024 | 726 | 0.040 |
Why?
|
Arthritis, Rheumatoid | 2 | 2013 | 3763 | 0.040 |
Why?
|
Biopsy | 1 | 2012 | 6816 | 0.040 |
Why?
|
Neoplasms | 2 | 2020 | 22386 | 0.040 |
Why?
|
Heart Transplantation | 1 | 2013 | 3291 | 0.040 |
Why?
|
Clinical Trials as Topic | 1 | 2014 | 8051 | 0.040 |
Why?
|
Mutation | 2 | 2025 | 30243 | 0.040 |
Why?
|
Heparin, Low-Molecular-Weight | 1 | 2020 | 344 | 0.040 |
Why?
|
Cytokines | 1 | 2013 | 7449 | 0.040 |
Why?
|
Signal Transduction | 2 | 2018 | 23638 | 0.040 |
Why?
|
Carcinoma, Renal Cell | 1 | 2013 | 3197 | 0.040 |
Why?
|
Enoxaparin | 1 | 2020 | 391 | 0.040 |
Why?
|
Anti-Bacterial Agents | 1 | 2016 | 7471 | 0.040 |
Why?
|
Neoplasm Staging | 1 | 2012 | 11249 | 0.030 |
Why?
|
Retrospective Studies | 3 | 2021 | 81834 | 0.030 |
Why?
|
Prognosis | 2 | 2020 | 30028 | 0.030 |
Why?
|
Endopeptidases | 1 | 2020 | 772 | 0.030 |
Why?
|
Immunomodulation | 1 | 2020 | 550 | 0.030 |
Why?
|
Autophagy | 1 | 2024 | 1349 | 0.030 |
Why?
|
Mice, Inbred NOD | 1 | 2020 | 1839 | 0.030 |
Why?
|
Mice, SCID | 1 | 2020 | 2633 | 0.030 |
Why?
|
Cell Proliferation | 2 | 2020 | 10494 | 0.030 |
Why?
|
Apoptosis | 2 | 2020 | 9526 | 0.030 |
Why?
|
Mice, Nude | 1 | 2020 | 3635 | 0.030 |
Why?
|
Polysaccharides | 1 | 2020 | 1024 | 0.030 |
Why?
|
Blood Cell Count | 1 | 2014 | 402 | 0.030 |
Why?
|
Taiwan | 1 | 2014 | 528 | 0.030 |
Why?
|
Seroepidemiologic Studies | 1 | 2014 | 406 | 0.030 |
Why?
|
Energy Metabolism | 1 | 2024 | 2901 | 0.030 |
Why?
|
Knee | 1 | 2014 | 279 | 0.030 |
Why?
|
Cell Line, Tumor | 2 | 2020 | 17149 | 0.020 |
Why?
|
Constriction, Pathologic | 1 | 2014 | 1103 | 0.020 |
Why?
|
Mitochondria | 1 | 2024 | 3672 | 0.020 |
Why?
|
Pregnancy | 1 | 2012 | 30179 | 0.020 |
Why?
|
Prostatic Neoplasms | 1 | 2013 | 11206 | 0.020 |
Why?
|
Cell Survival | 1 | 2020 | 5801 | 0.020 |
Why?
|
Tacrolimus | 1 | 2013 | 750 | 0.020 |
Why?
|
Fatal Outcome | 1 | 2014 | 1840 | 0.020 |
Why?
|
Drug Resistance, Bacterial | 1 | 2016 | 1064 | 0.020 |
Why?
|
China | 1 | 2014 | 2398 | 0.020 |
Why?
|
Heart Failure | 1 | 2012 | 11857 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2020 | 10784 | 0.020 |
Why?
|
Disease Susceptibility | 1 | 2014 | 1797 | 0.020 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2024 | 9425 | 0.020 |
Why?
|
Amyloidosis | 1 | 2012 | 879 | 0.010 |
Why?
|
Myocarditis | 1 | 2012 | 804 | 0.010 |
Why?
|
Anticoagulants | 1 | 2020 | 4840 | 0.010 |
Why?
|
Antirheumatic Agents | 1 | 2013 | 1374 | 0.010 |
Why?
|
Risk | 1 | 2014 | 9642 | 0.010 |
Why?
|
Odds Ratio | 1 | 2014 | 9687 | 0.010 |
Why?
|
Logistic Models | 1 | 2016 | 13324 | 0.010 |
Why?
|
Skin | 1 | 2014 | 4520 | 0.010 |
Why?
|
Comorbidity | 1 | 2014 | 10601 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2014 | 22293 | 0.010 |
Why?
|
Risk Factors | 1 | 2016 | 74915 | 0.000 |
Why?
|
Concepts
(177)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(39)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_